Zusammenfassung
Trotz der sicher belegten Wirksamkeit der Neuroleptika zeigt keine der spezifischen Substanzen den erwünschten therapeutischen Erfolg in dem gewünschten Umfang: Es respondiert jeweils nur ein Teil der psychotisch Kranken, der therapeutische Effekt führt häufig nicht zur Remission, und oft treten unerwünschte Nebenwirkungen auf, die sogar zum Absetzen der Medikation zwingen können. In einer solchen Situation wären substanzspezifische Prädiktoren der therapeutischen Wirkung zum Zwecke der Optimierung der antipsychotischen Behandlung sehr hilfreich. Die bisherigen Untersuchungen zur Prädiktion des Therapieeffekts konnten aber keine sicheren Indikatoren extrahieren.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arranz M, Collier D, Sodhi M et al. (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346:281–282
Arranz MJ, Collier DA, Munro J et al. (1996) Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 217:177–178
Burnet PWJ, Harrison PJ (1995) Genetic variation of the 5-HT2a receptor and response to clozapine. Lancet 346:909
Cole JO, Goldberg SC, David JM (1966) Drugs in the treatment of psychosis: controlled studies. In: Solomon P (ed) Psychiatric drugs. Grune & Stratton, New York, pp 153–180
Goldman D, Lappalainen J, Ozaki N et al. (1995) Natural structural variants of human serotonin receptors. Psychiatr Genet 5 (Suppl 1):S22
Kennedy JL, Petronis A, Macciardi FM, Van Tol HHM, Cola P, Meltzer Y (1994) The D4 dopamine receptor gene, clozapine response, and schizophrenia. Neuropsychopharmacology 10:897S (Abstract)
Kohn Y, Ebstein RP, Heresco-Levy U et al. (1997) Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol 7:39–43
Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D (1996a) Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 153:1092–1094
Malhotra AK, Goldman D, Ozaki N et al. (1996b) Clozapine response and the 5HT2C Cys23Ser polymorphism. Neuroreport 7:2100–2102
Masellis M, Paterson AD, Badri F, Lieberman JA, Meltzer HY, Cavazzoni P, Kennedy JL (1995) Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 346:1108
McDowell DM, Kleber HD (1994) MDMA: Its history and pharmacology. Psychiatr Ann 24:127–130
Meltzer HY (1994) An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 (Suppl B):47–52
Nimgaonkar VL, Wessely S, Tune LE, Murray RM (1988) Response to drugs in schizophrenia: the influence of family history, obstetric complications and ventricular enlargement. Psychol Med 18:583–592
Nöthen MM, Rietschel M, Erdmann J, Oberlander H, Möller H-J, Naber D, Propping P (1995) Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 346:908–909
Propping P, Nöthen MM (1995) Genetic variation of CNS receptors — a new perspective for pharmacogenetics. Pharmacogenetics 5:318–325
Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J (1994) Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 51:912–917
Reynolds GP, Mason SL (1994) Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 63:1576–1577
Rietschel M, Naber D, Oberländer H et al. (1996) Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 15:491–496
Rietschel M, Naber D, Fimmers R, Möller H-J, Propping P, Nöthen MM (1997) Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 8:1999–2003
Seeman P, Guan H-C, Van Tol HHM (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365:441–445
Shaikh S, Collier D, Kerwin RW, Pilowsky LS, Gill M, Xu WM, Thornton A (1993) Dopamine D4 receptor subtypes and response to clozapine. Lancet 341:116
Shaikh S, Collier DA, Sham P et al. (1995) Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet 60:541–545
Sodhi MS, Arranz MJ, Curtis D et al. (1995) Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7:169–172
Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614
Verga M, Macciardi F, Cohen S, Pedrini S, Smeraldi E (1997) No association between schizophrenia and the serotonin receptor 5-HTR2a in an Italian population. Am J Med Genet 74:21–25
Williams J, Spurlock G, McGuffin P et al. (for the European Multicentre Association Study of Schizophrenia (EMASS) Group) (1996) Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet 347:1294–1296
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Maier, W., Rietschel, M. (1998). Pharmakogenetische Determination der therapeutischen Wirkungen von Clozapin. In: Bandelow, B., Rüther, E. (eds) Therapie mit klassischen und neuen Neuroleptika. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72152-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-72152-6_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-64095-0
Online ISBN: 978-3-642-72152-6
eBook Packages: Springer Book Archive